Zacks highlights commentary from People and Picks Member «Neurodoc».
For more Voice of the People, visit http://at.zacks.com/?id=7872
Featured Post
Buy BIIB
Biogen Idec (BIIB) has Avonex (still very useful as first line therapy for MS), Tysabri, extremely useful despite the PML risk, and this new oral drug very likely to be approved later next year, and could be the preferred first-line treatment (see below). BIIB is now a fixture in my porfolio.
Related Quotes Sym. Price Chg. BIIB Trade News 99.6 0.95
MARKET TALK: Biogen’s MS Drug Has ‘Blue Sky Potential’ Jun 22, 2011 13:50:20 (ET) 1:50 (Dow Jones) There’s “blue sky potential” for Biogen’s pill BG12 to become the “corner stone” multiple-sclerosis therapeutic, notes Credit Suisse after upgrading the company’s rating to buy.
The firm is optimistic about BG12’s commercial prospects and says it’s a factor that could lead to BIIB having the “most robust long term revenue and earning profile” among large-cap biotech companies. BG12’s success “will likely significantly drive down” BIIB’s R&D cost base as a percentage of revenues, Credit Suisse says.
BIIB climbs 1.7% to $100.49. The stock has soared 102% in the last year.
The most recent picks by «Neurodoc» are:
A buy rating on TNS, Inc. (TNS),
a buy rating on CIBER, Inc. (CBR) and
a buy rating on Viacom (VIA).
About the Zacks Community
In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to http://at.zacks.com/?id=7867.
